(Shared Resources-ICTBD Core) The overall objective of the Integrated Clinical and Tissue Biorepository/Biomarker Data Base (ICTBD) Core is to enhance and upgrade our current ICTBD Core which is integrated with our Clinical Resource Core. This will be accomplished through a multi-dimensional translational research approach which leverages the Partnership's research/outreach Cores, clinical networks, community partners, and academic partners developed through the 1st U54 funding cycle (2009-2015). The Partnership uses Translational Research according to the two translational blocks (T1- Basic/Biomedical Research and T2- Clinical/Implementation Research). During the 2nd U54 Cycle (2015-2020), the Partnership proposes to utilize the ICTBD Core to both enhance existing T1 activities, and facilitate the transfer of projects developed in 1st U54 cycle from T1 to T2. We will accomplish this through the following: 1) continue building networks to enhance biospecimen/data collection and facilitate translational research, 2) provide patient consent/engagement into biospecimen and clinical research protocols, 3) facilitate a platform of bi-directional exchange, education/training, and information dissemination between the Partnership's T1/T2 activities and the Community Cancer Outreach Core, 4) provide administrative support for T1 to T2 transition such as IRB preparation, monitoring, and patient recruitment to enhance underrepresented patient participation in clinical trials, and 5) work in partnership with our community partners and community oncologists to continue to build and sustain a comprehensive biospecimen repository with focus on breast, colon, and prostate cancers from African Americans and Latinos for the purpose of identification of novel markers for assessing risk of cancer incidence and progression that may be unique to ethnic groups and reduce cancer health disparities. These activities will dually enrich both sides of the CDU/UCLA Partnership by bolstering CDU's institutional capacity for translational research with UCLA-JCCC resources, and diversifying access for UCLA-JCCC to improve engagement of underrepresented participants in research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA143931-09
Application #
9548920
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
9
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Charles R. Drew University of Medicine & Science
Department
Type
DUNS #
785877408
City
Los Angeles
State
CA
Country
United States
Zip Code
90059
Boonyaratanakornkit, Viroj; Hamilton, Nalo; Márquez-Garbán, Diana C et al. (2018) Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer. Mol Cell Endocrinol 466:51-72
Chung, Seyung S; Dutta, Pranabananda; Austin, David et al. (2018) Combination of resveratrol and 5-flurouracil enhanced anti-telomerase activity and apoptosis by inhibiting STAT3 and Akt signaling pathways in human colorectal cancer cells. Oncotarget 9:32943-32957
Maxwell, Annette E; Young, Sandra; Moe, Emily et al. (2018) Understanding Factors that Influence Health Care Utilization Among Mixtec and Zapotec Women in a Farmworker Community in California. J Community Health 43:356-365
Maxwell, Annette E; Castillo, Laura; Arce, Anthony A et al. (2018) Eating Veggies Is Fun! An Implementation Pilot Study in Partnership With a YMCA in South Los Angeles. Prev Chronic Dis 15:E132
Elshimali, Yahya I; Wu, Yong; Khaddour, Hussein et al. (2018) Optimization Of Cancer Treatment Through Overcoming Drug Resistance. J Cancer Res Oncobiol 1:
Hamilton, Nalo; Austin, David; Márquez-Garbán, Diana et al. (2017) Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. Int J Mol Sci 18:
La, V; Fujikawa, R; Janzen, D M et al. (2017) Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy. NPJ Precis Oncol 1:
Wu, Y; Vadgama, J V (2017) Androgen Receptor as a Potential Target for Treatment of Breast Cancer. Int J Cancer Res Mol Mech 3:
Wu, Yong; Yu, Xiaoting; Yi, Xianghua et al. (2017) Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x-SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis. Cancer Res 77:1383-1394
Wang, Piwen; Solorzano, Walter; Diaz, Tanya et al. (2017) Arctigenin inhibits prostate tumor cell growth in vitro and in vivo. Clin Nutr Exp 13:1-11

Showing the most recent 10 out of 90 publications